Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC1812810.15690/vramn18128CARDIOLOGY AND CARDIOVASCULAR SURGERY: CURRENT ISSUESАКТУАЛЬНЫЕ ВОПРОСЫ КАРДИОЛОГИИ И СЕРДЕЧНО-СОСУДИСТОЙ ХИРУРГИИResearch ArticleCardiac arrhythmias during pregnancy: efficacy and safety of antiarrhythmic therapyНарушения сердечного ритма во время беременности: вопросы эффективности и безопасности антиаритмической терапииhttps://orcid.org/0000-0003-0514-91141032-9122RoytbergGrigory E.РойтбергГригорий Ефимович
Russian Federation

MD, PhD, Professor, Academician of the RAS

д.м.н., профессор, академик РАН

contact@medicina.ruhttps://orcid.org/0000-0002-4076-28498198-1964SlastnikovaIrina D.СластниковаИрина Дмитриевна
Russian Federation

МD, PhD, Assistant Professor

к.м.н., доцент

slastid@mail.ruhttps://orcid.org/0000-0001-8527-46819987-6100SharkhunOlga O.ШархунОльга Олеговна
Russian Federation

MD, PhD, Assistant Professor, Professor

д.м.н., доцент, профессор

olga_sharkhun@mail.ruPirogov Russian National Research Medical University (Pirogov Medical University)Российский национальный исследовательский медицинский университет имени Н.И. Пирогова19062026812991062610202518042026Copyright ©; 2026, "Paediatrician" Publishers LLCCopyright ©; 2026, Издательство "Педиатръ"2026"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/about/submissionshttps://vestnikramn.spr-journal.ru/jour/article/view/18128

During pregnancy, there is an increased tendency to develop rhythm disturbances. The treatment of arrhythmias in pregnant women, including the use of antiarrhythmic drugs, has significant features and presents significant problems for medical professionals. The use of most drugs in this group during pregnancy is unsafe due to potential teratogenic effects. Some drugs can cause complications such as birth defects, pregnancy loss, premature birth, infant death, or developmental delays. Preconception counseling regarding the risk of arrhythmia recurrence during pregnancy, consideration of ablation before pregnancy, effective treatment, and close monitoring of high-risk patients can be critical to a successful pregnancy outcome for both mother and fetus. Much attention in the article is paid to the safety of the treatment of rhythm disorders during pregnancy, the features of the use of specific antiarrhythmic drugs, their effect on the body of the mother and fetus, as well as the algorithm of their use in various types of arrhythmias are considered in detail.

Во время беременности наблюдается повышенная склонность к возникновению нарушений сердечного ритма. Лечение аритмий у беременных женщин, включая применение антиаритмических препаратов, имеет существенные особенности и представляет значительные проблемы для медицинских работников. Использование большинства препаратов этой группы в период беременности небезопасно из-за возможного негативного тератогенного действия. Некоторые препараты могут вызывать такие осложнения, как врожденные дефекты плода, потеря беременности, преждевременные роды, смерть младенцев или нарушение их развития. Прегравидарное консультирование относительно риска рецидива аритмии во время беременности, рассмотрение возможности абляции до беременности, эффективное лечение и тщательное наблюдение за пациентками из группы высокого риска могут иметь решающее значение для успешного исхода беременности для матери и плода. В статье большое внимание уделено вопросам безопасности лечения нарушений ритма при беременности, подробно рассмотрены особенности применения конкретных антиаритмических препаратов, их влияние на организм матери и плода, а также алгоритм их использования при различных видах аритмий.

pregnancyarrhythmiasantiarrhythmic drugscardioversioncatheter ablationsafetyside effectsteratogenicityбеременностьаритмииантиаритмические препаратыкардиоверсиякатетерная абляциябезопасностьпобочные эффектытератогенностьElkayam U, Goland S, Pieper PG, et al. High-Risk Cardiac Disease in Pregnancy. J Am Coll Cardiol. 2016;68(4):396–410. doi: https://doi.org/10.1016/j.jacc.2016.05.048De Backer J, Haugaa K, Hasselberg N, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur. Heart J. 2025;46(43):4462–4568. doi: https://doi.org/10.1093/eurheartj/ehaf193Vaidya VR, Arora S, Patel N, et al. Burden of Arrhythmia in Pregnancy. Circulation. 2017;135(6):619–621. doi: 10.1161/CIRCULATIONAHA.116.026681Silversides CK, Grewal J, Mason J, et al. Pregnancy outcomes in women with heart disease: The CARPREG II Study. J Am Coll Cardiol. 2018;71(21):2419–2430. doi: https://doi.org/10.1016/j.jacc.2018.02.076Joglar JA, Kapa S, Saarel EV, et al. 2023 HRS Expert Consensus Statement on the Management of Arrhythmias During Pregnancy. Heart Rhythm. 2023;20(10):е175–е264. doi: https://doi.org/10.1016/j.hrthm.2023.05.017Brucker MC, King TL. The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule. J Midwifery Womens Health. 2017;62(3):308–316. doi: https://doi.org/10.1111/jmwh.12611Halpern DG, Weinberg CR, Pinnelas R, et al. Use of medication for cardiovascular disease during pregnanc: JACC State-of-the-Art Reviewy. J Am Coll Cardiol. 2019;73:457–476. doi: https://doi.org/10.1016/j.jacc.2018.10.075Tamirisa KP, Dye C, Bond RM, et al. Arrhythmias and Heart Failure in Pregnancy: A Dialogue on Multidisciplinary Collaboration. J Cardiovasc Dev Dis. 2022;9(7):199. doi: https://doi.org/10.3390/jcdd9070199Mariani MV, Pierucci N, La Fazia VM, et al. Antiarrhythmic Drug Use in Pregnancy: Considerations and Safety Profiles. J Cardiovasc Dev Dis. 2024;11(8):243. doi: https://doi.org/10.3390/jcdd11080243Linde C, Bongiorni MG, Birgersdotter-Green U, et al. Sex differences in cardiac arrhythmia: A consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace. 2018;20(10):1565–1565ao. doi: https://doi.org/10.1093/europace/euy067Fischer AJ, Diller GP, Uebing A, et al Antiarrhythmic drugs — Safety and efficacy during pregnancy. Herzschrittmacherther Elektrophysiol. 2021;32(2):145–151. doi: https://doi.org/10.1007/s00399-021-00759-2Sridharan S, Sullivan I, Tomek V, et al. Flecainide versus digoxin for fetal supraventricular tachycardia: Comparison of two drug treatment protocols. Heart Rhythm. 2016;13(9):1913–1919. doi: https://doi.org/10.1016/j.hrthm.2016.03.023Strizek B, Berg C, Gottschalk I, et al. High-dose flecainide is the most effective treatment of fetal supraventricular tachycardia. Heart Rhythm. 2016;13(6):1283–1288. doi: https://doi.org/10.1016/j.hrthm.2016.01.029Bateman BT, Patorno E, Desai RJ, et al. Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. Pediatrics. 2016;138(3):e20160731. doi: https://doi.org/10.1542/peds.2016-0731Bergman JEH, Lutke LR, Gans ROB, et al. Beta-blocker use in pregnancy and risk of specific congenital anomalies: a European case-malformed control study. Drug Saf. 2018;41(4):415–427. doi: https://doi.org/10.1007/s40264-017-0627-xGrewal J, Siu SC, Lee T, et al. Impact of beta-blockers on birth weight in a high-risk cohort of pregnant women with CVD. J Am Coll Cardiol. 2020;75(21):2751–2752. doi: https://doi.org/10.1016/j.jacc.2020.03.068Tanaka K, Tanaka H, Kamiya C, et al. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J. 2016;80(10):2221–2226. doi: https://doi.org/10.1253/circj.CJ-15-0617Alsaied T, Baskar S, Fares M, et al. First-line antiarrhythmic transplacental treatment for fetal tachyarrhythmia: A systematic review and meta-analysis. J Am Heart Assoc. 2017;6(12):e007164. doi: https://doi.org/10.1161/JAHA.117.007164Yaksh A, van der Does LJ, Lanters EA, et al. Pharmacological therapy of tachyarrhythmias during pregnancy. Arrhythm Electrophysiol Rev. 2016;5(1):41–44. doi: https://doi.org/10.15420/AER.2016.1.2.Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation. 2014;129(21):2183–2242. doi: https://doi.org/10.1161/01.cir.0000437597.44550.5dCarvalho SJ. Fetal dysrhythmias. Best Pract Res Clin Obstet Gynaecol. 2019;58:28–41. doi: https://doi.org/10.1016/j.bpobgyn.2019.01.002Saad AF, Monsivais L, Pacheco LD. Digoxin therapy of fetal superior ventricular tachycardia: are digoxin serum levels reliable? AJP Rep. 2016;6(3):e272–276. doi: https://doi.org/10.1055/s-0036-1586241Попов С.В., Давтян К.В., Шубик Ю.В., и др. Наджелудочковые тахикардии. Клинические рекомендации 2025 // Российский кардиологический журнал. — 2025. — Т. 30. — № 7. — С. 6448. [Popov SV, Davtyan KV, Shubik YuV, et al. 2025 Clinical practice guidelines for Supraventricular tachycardias. Russian Journal of Cardiology. 2025;30(7):6448. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2025-6448Van Gelder IC, Rienstra M, Bunting KV, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314–3414. doi: https://doi.org/10.1093/eurheartj/ehae176Georgiopoulos G, Tsiachris D, Kordalis A, et al. Pharmacotherapeutic strategies for atrial fibrillation in pregnancy. Expert Opin Pharmacother. 2019;20(13):1625–1636. doi: https://doi.org/10.1080/14656566.2019.1621290Lewis G, Currie P. Atrial fibrillation during pregnancy: cardioversion with flecainide. Br J Hosp Med (Lond). 2015;76(12): 720–721. doi: https://doi.org/10.12968/hmed.2015.76.12.720Lameijer H, Aalberts JJ, van Veldhuisen DJ, et al. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. Thromb Res. 2018;169:123–127. doi: https://doi.org/10.1016/j.thromres.2018.07.022Areia AL, Mota-Pinto A. Experience with direct oral anticoagulants in pregnancy — a systematic review. J Perinat Med. 2022;50(4):457–461. doi: https://doi.org/10.1515/jpm-2021-0457Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):1677–1749. doi: https://doi.org/10.1016/j.jacc.2017.10.053Tfelt-Hansen J, Winkel BG, de Riva M, et al. The “10 commandments” for the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2023;44(3):176–177. doi: https://doi.org/10.1093/eurheartj/ehac699Roston TM, van der Werf C, Cheung CC, et al. Caring for the pregnant woman with an inherited arrhythmia syndrome. Heart Rhythm. 2020;17(2):341–348. doi: https://doi.org/10.1016/j.hrthm.2019.08.004Голицын С.П., Голухова Е.З., Михайлов Е.Н., и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2025 // Российский кардиологический журнал. — 2025. — Т. 30. — № 11. — С. 6668. [Golitsyn SP, Golukhova EZ, Mikhailov EN, et al. 2025 Clinical practice guidelines for Atrial fibrillation and flutter. Russian Journal of Cardiology. 2025;30(11):6668. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2025-6668Михайлов Е.Н., Гизатулина Т.П., Лебедев Д.С., и др. Желудочковые нарушения ритма сердца. Внезапная сердечная смерть. Клинические рекомендации 2025 // Российский кардиологический журнал. — 2025. — Т. 30. — № 11. — С. 6670. [Mikhailov EN, Gizatulina TP, Lebedev DS, et al. Clinical practice guidelines for Ventricular arrhythmias of the heart and Sudden cardiac death. Russian Journal of Cardiology. 2025;30(11):6670. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2025-6670